StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) company profile

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

About Krystal Biotech

Biological Products, (No Diagnostic Substances), SIC 2836

The company discovers, manufactures, and commercializes redosable genetic medicines designed to treat rare and debilitating conditions with substantial unmet medical needs. Utilizing a proprietary gene therapy platform engineered from herpes simplex virus-1, it produces targeted therapies that can be administered non-invasively at healthcare facilities or in home environments. Its principal commercial offering is Vyjuvek, an approved topical treatment for wounds caused by dystrophic epidermolysis bullosa. In addition to developing pipeline candidates for respiratory, dermatological, and ophthalmic diseases, the business addresses aesthetic conditions through its dedicated subsidiary, primarily serving pediatric and adult patients affected by serious genetic disorders.

The company operates two commercial-scale manufacturing sites situated in Pennsylvania, from which it distributes gene therapies internationally. Commercial activities are conducted directly across the United States, Japan, and major European markets including Germany and France, alongside planned expansions into broader Western European territories. It further distributes products via regional specialty partner networks in Central and Eastern Europe, the Middle East, and Israel. The provided text mentions no details regarding the location of the corporate headquarters.

Summary of the business section of Krystal Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Krystal Biotech, Inc.
Headquarters
Pittsburgh, PA
Address
2100 Wharton Street, Suite 701 15203
Phone
(412) 586-5830
Employees
295, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
KPMG LLP, Pittsburgh

Stock & identifiers

Ticker
KRYS
Exchange
Nasdaq
IPO date
Sep 20, 2017
Shares outstanding
30M, Jul 28, 2026
Public float
$3.50B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1711279
CUSIP
501147102
ISIN
US5011471027
FIGI
BBG00HDGRHH7
Share class FIGI
BBG00HDGRHJ5
LEI
549300YONUY68210OE41
EIN
82-1080209

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Krish S. KrishnanPresident and CEO, Director1,567,863
Suma KrishnanPresident, R&D, Director1,512,362
John Charles ThomasEVP, General Counsel1,000
Laurent Louis Jean GouxEVP, Head of International919
Kathryn RomanoChief Accounting Officer22,366
Dino A. RossiDirector46,500
Daniel JanneyDirector76,409
Catherine MazzaccoDirector–
Julian S. GangolliDirector20,000
Christopher MasonDirector–
Everett Rand SutherlandDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.44M$22.80M$4.60M$411$120
FY2024$15.60M$19.83M$5.65M$283$114
FY2023$6.22M$11.69M$2.89M$224$115
FY2022$3.26M$4.30M$2.85M$143$111
FY2021$7.35M$6.80M$5.88M$126$125
FY2020$763.77K$763.77K$1.30M$108$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Krish S. Krishnan
Chair and Chief Executive Officer
$846.17K$682.40K$4.10M$4.68M$134.00K$10.44M-33%
Kathryn A. Romano
Chief Accounting Officer
$437.50K$223.26K$394.35K$1.19M$14.00K$2.26M-26%
Suma M. Krishnan
President, R&D
$677.50K$414.92K$2.87M$2.97M$14.00K$6.95M-16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 20, 2017
Offer price
$10.00
Securities offered
3,960,000
Gross proceeds
$39.60M
Exchange
Nasdaq
First trading day
Sep 20, 2017
First-day close
$10.64+6.4%
Lock-up ends (est.)
Mar 19, 2018

“The initial public offering price of our common stock is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 11, 2026, we had 295 full-time employees, primarily engaged in research and development, pre-clinical and clinical trials, manufacturing VYJUVEK and our pipeline product candidates, commercial activities for VYJUVEK in the United States, the European Union, and Japan, regulatory matters, strategic business development, finance and other t”

Corporate history

Events identified from SEC filings

See a number that looks wrong?